Lenacapavir posts 100% HIV prevention in PURPOSE 1: what it means

Lenacapavir posts 100% HIV prevention in PURPOSE 1: what it means

Gilead reported that lenacapavir achieved 100% efficacy in the Phase 3 PURPOSE 1 trial for HIV prevention in cisgender women. The result strengthens the company's PrEP franchise and raises the next questions around approval timing, label expansion, and commercial positioning.

IntelligenceRegulatory Impact▾

FDA and EMA decisions frame this story. Regulatory relevance is high for HIV, with lenacapavir and Truvada most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• Gilead's Phase 3 PURPOSE 1 trial demonstrated 100% efficacy for lenacapavir in HIV prevention among cisgender women, marking a significant efficacy readout for the injectable candidate.
• Yeztugo (lenacapavir) is FDA-indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition, with a requirement for negative HIV-1 testing prior to initiation.
• A Phase 3 clinical study (NCT07047716) is evaluating lenacapavir as a once-yearly injection for HIV pre-exposure prophylaxis, representing a potential next step in the long-acting PrEP pipeline.
• The PURPOSE 1 result establishes a clinical benchmark for the lenacapavir formulation and signals potential for label expansion discussions.

IntelligenceCompetitive Intelligence▾

Gilead Sciences are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.

The Development

Gilead announced that its HIV-1 capsid inhibitor lenacapavir demonstrated 100% efficacy in the interim analysis of the Phase 3 PURPOSE 1 trial for HIV prevention in cisgender women. Following this efficacy signal, Gilead moved forward with regulatory submissions that culminated in the approval of Yeztugo (lenacapavir), indicated for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. The label specifies that individuals must have a negative HIV-1 test prior to initiating Yeztugo.

The approval separates investigational trial findings from marketed product indication. PURPOSE 1 provided the efficacy signal; Yeztugo's label reflects the FDA's authorized use and patient population. The distinction matters for BD teams evaluating the asset's commercial scope and for investors tracking label expansion potential.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for HIV. Expect implications for pricing, access, and launch sequencing.

Clinical Evidence and Approved Use

Lenacapavir is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor. The Phase 3 PURPOSE 1 trial demonstrated 100% efficacy for lenacapavir in HIV prevention, establishing an efficacy signal for the candidate in the cisgender women population studied.

The approved indication for Yeztugo covers adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. This population definition and the requirement for baseline HIV-1 testing set the parameters for initial clinical use. By contrast, Truvada (emtricitabine and tenofovir disoproxil fumarate) is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in adults at high risk. Both are FDA-approved PrEP options with different routes of administration: Truvada is oral, while Yeztugo is injectable.

The PURPOSE 1 efficacy signal supports the clinical potential of lenacapavir for HIV prevention, though real-world uptake will depend on execution, access, and payer positioning.

IntelligenceStrategic Takeaways▾

Gilead's Phase 3 PURPOSE 1 trial demonstrated 100% efficacy for lenacapavir in HIV prevention among cisgender women, marking a significant efficacy readout for the injectable candidate. Yeztugo (lenacapavir) is FDA-indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition , with a requirement for

Pipeline Progress and Regulatory Pathway

Gilead is advancing lenacapavir across multiple indications and formulations. NCT07047716 is a Phase 3 clinical study evaluating lenacapavir as a once-yearly injection for HIV pre-exposure prophylaxis, representing a potential next-generation dosing interval under investigation. If that study succeeds, a once-yearly formulation could offer an alternative to the current approved regimen.

Beyond PrEP, Gilead is studying lenacapavir in treatment settings. NCT06532656 is a Phase 2/3 study of bictegravir/lenacapavir in children and adolescents with HIV-1, currently active but not recruiting. NCT06630299 is a Phase 3 trial comparing an oral weekly islatravir/lenacapavir regimen with standard of care in virologically suppressed people with HIV-1, also active but not recruiting. These programs explore lenacapavir's utility beyond prevention.

Implementation and real-world studies are underway. NCT07473778 is an implementation study of lenacapavir pre-exposure prophylaxis for HIV prevention, currently recruiting. Such studies typically assess feasibility, acceptability, and outcomes in community or clinical settings outside controlled trials.

IntelligenceEvidence Quality▾

Grounded in 2 regulatory sources and 1 peer-reviewed source.

Implications for Pharma Teams

The PURPOSE 1 100% efficacy readout establishes a clinical benchmark for the lenacapavir formulation. For business development teams, the next questions center on label expansion (additional populations, formulations), regulatory feedback on other indications, and payer positioning.

Investors tracking long-acting HIV prevention should note that the efficacy signal is population-specific: PURPOSE 1 enrolled cisgender women. Label expansion to other populations would require additional trial data or regulatory submissions. The evidence does not specify whether such studies are planned or underway.

The evidence does not provide efficacy data for other long-acting PrEP candidates or timelines for their regulatory decisions. Gilead's current pipeline in this segment includes the approved Yeztugo regimen and the ongoing once-yearly study.

Access and reimbursement remain important variables. Long-acting injectables often carry different cost structures than daily oral regimens, which can affect payer coverage and patient out-of-pocket exposure. The evidence does not include pricing, reimbursement, or real-world uptake data.

What to Watch Next

Several catalysts warrant monitoring:

• Once-yearly study readout: NCT07047716 is evaluating lenacapavir as a once-yearly injection for HIV pre-exposure prophylaxis. Results from this trial will inform whether a less frequent dosing interval is achievable.
• Implementation study progress: NCT07473778 is currently recruiting for an implementation study of lenacapavir pre-exposure prophylaxis. Real-world data on tolerability and clinical outcomes will inform market positioning and payer discussions.
• Label expansion discussions: Regulatory feedback on additional populations or formulations will signal the scope of Yeztugo's addressable market. The evidence does not detail planned submissions.
• Treatment program updates: NCT06532656 (bictegravir/lenacapavir in children and adolescents with HIV-1) and NCT06630299 (oral weekly islatravir/lenacapavir in virologically suppressed adults) are active but not recruiting. Future readouts or enrollment updates could inform the breadth of lenacapavir's clinical utility.

Frequently Asked Questions

Related profiles

• Gilead Sciences
• lenacapavir
• TRUVADA

Related coverage

• Lenacapavir posts 100% HIV prevention in PURPOSE 1
• Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials
• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial